[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1977

Androgens, Estrogens, and the Ultimate Height in XO Gonadal Dysgenesis

Author Affiliations

From the Department of Internal Medicine "D", Beilinson Medical Center, Petah-Tikva, the Endocrine Laboratory of the Sick Fund, and Tel Aviv University Medical School, Tel Aviv, Israel.

Am J Dis Child. 1977;131(6):648-649. doi:10.1001/archpedi.1977.02120190042008
Abstract

• We observed 40 patients with 45,X gonadal dysgenesis from the age of 13 to 15 years until the age of 18 to 21 years. The ultimate height of the 12 nontreated patients was 143.2 cm. Of 15 patients treated with nandrolone phenpropionate or methandrostenolone, the ultimate height was 143.3 cm, and of 13 patients treated with ethinyl estradiol, the height reached was 144.1 cm. The mean height of ten patients first seen at the age of 25 to 31 years was 140.1 cm. The mean height at any age was almost identical in all the groups. The growth velocity was somewhat accelerated by anabolic steroids and to a lesser extent, by estrogens only during the first year of therapy, and this did not influence the ultimate height. We saw no deleterious effects of the estrogens. In all the groups, there were patients who grew for some time at rates of up to 4 to 6 cm/yr. Therefore, long-term follow-up studies are needed for the evaluation of the effects of any treatment.

(Am J Dis Child 131:648-649, 1977)

×